UNITED STATES
NUCLEAR REGULATORY COMMISSION
WASHINGTON, D.C. 20555-0001

May 7, 1996

JEWISH HOSPITAL
ATTN: Dr. PAUL A. FELLER, PH.D.
Radiation Safety Officer

3200 BURNET AVENUE
CINCINNATI, OH 45229

SUBJECT: ONE-TIME EXTENSION OF LICENSE EXPIRATION DATE
LICENSE NUMBER 34-00855-07, DOCKET NUMBER 3014033

Dear Dr. PAUL A. FELLER, PH.D.

On January 16, 1996, the Nuclear Regulatory Commission (NRC) amended its regulations in 10 CFR 30, 40, and 70 to extend the expiration date of certain byproduct, source, and special nuclear material licenses by five years (61 FR 1109). The above referenced license was extended by this rulemaking and will now expire on January 31, 2001. Your license will not be amended to show this extended date until the next routine licensing action. Until then, you may provide copies of this letter to vendors and other interested parties as evidence that the license has been extended as a result of the rule.

The extended license authorizes the same activities and contains the same limitations as it previously did. There will be no change in the frequency that the NRC inspects activities authorized by this license.

The amended rules state that in the case of licensees who are granted extensions and who have a currently pending renewal application for that extended license, the application will be considered withdrawn by the licensee and any renewal fees paid by the licensee for that application will be refunded. This will apply to licenses with expiration dates after July 1, 1995, for which renewal applications and the appropriate fees have been submitted and the renewal is still pending. Refunds will be mailed to licensees under separate cover.

All licensees, including those whose renewal applications were withdrawn by this rulemaking, who wish to change their radiation safety programs must request amendment of their licenses to reflect these changes. Amendment requests must include the correct amendment fee since the NRC cannot apply pending renewal refund balances toward amendment fees.

If you have any questions regarding this letter, please contact the individual below.

John R. Madera, Division of Nuclear Materials Safety - (708) 829-9834

Thank you for your cooperation in this matter.

Sincerely,

Donald A. Cool, Director
Division of Industrial and Medical Nuclear Safety
Office of Nuclear Materials Safety and Safeguards

NRC FORM 374 (10-89)

U.S. NUCLEAR REGULATORY COMMISSION

Amendment No. 17

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 39, 40 and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

Licensee	
1. The Jewish Hospital	In accordance with letter dated September 30, 1994 3. License number 34-00855-07 is amended in its entirety to read as follows:
2. 3200 Burnet Avenue Cincinnati, OH 45229	4. Expiration date January 31, 1996
	5. Docket or Reference No. 030-14033

6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any one time under this license
A. Any byproduct material identified in 10 CFR 35.100	A. Any radiopharmaceutical identified in 10 CFR 35.100	A. As needed
B. Any byproduct material identified in 10 CFR 35.200	B. Any radiopharmaceutical identified in 10 CFR 35.200	B. As needed
C. Any byproduct material identified in 10 CFR 35.300	C. Any radiopharmaceutical identified in 10 CFR 35.300	C. As needed
D. Any byproduct material identified in 10 CFR 35.400	D. Any brachytherapy sources identified in 10 CFR 35.400	D. As needed
E. Any byproduct material identified in 10 CFR 35.500	E. Sealed sources identified in 10 CFR 35.500	E. As needed
F. Any byproduct material identified in 10 CFR 31.11	F. Prepackaged Kits	F. As needed
G. Cesium-137	G. Sealed source (Tech Ops Model 77302)	G. One source not to exceed 165 millicuries

NRC Form 374A (5-84) U.S. NUCLEAR REGULATORY COMMISSION

PAGE 2 OF 6 PAGES

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License number: 34-00855-07

Docket or Reference number: 030-14033

Amendment No. 17

6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any one time under this license
H. Cesium-137	H. Sealed source (ORIS/CBL Model CSU-16)	H. One source not to exceed 1700 curies

9. Authorized Use:

A. Medical use described in 10 CFR 35.100.

B. Medical use described in 10 CFR 35.200.

C. Medical use described in 10 CFR 35.300.

D. Medical use described in 10 CFR 35.400.

E. Medical use described in 10 CFR 35.500 in devices which have been evaluated and approved for licensing purposes by the U.S. Nuclear Regulatory Commission or an Agreement State.

F. In vitro studies.

G. For use in Nuclear Associates/Technical Operations Model 773 instrument calibrator for survey instrument calibration.

H. To be used for the irradiation of the biological materials.

CONDITIONS

NRC Form 374A (5-84)

U.S. NUCLEAR REGULATORY COMMISSION

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License number
34-00855-07

Docket or Reference number
030-14033

Amendment No. 17

12. Authorized Users (Continued)

V. Peter Fried, M.D., for material in 10 CFR 35.300 and 35.400.

W. Rodney P. Geier, M.D., for material in 10 CFR 35.400 and Phosphorus-32 as colloidal chromic phosphate for intracavitary treatment of malignant effusions.

X. Ralph J. Wright, III, M.D., for material in 10 CFR 35.400 and Phosphorus-32 as colloidal chromic phosphate for intracavitary treatment of malignant effusions.

Y. Elizabeth Levic, M.D., for material 10 CFR 35.400.

Z. John Breneman, M.D., for material in 10 CFR 35.300 and 35.400.

AA. Kevin Redmond, M.D., for material 10 CFR 35.300 and 35.400.

BB. Alex J. Chronis, M.D., for material in 10 CFR 35.100 and 35.200.

CC. William L. Barrett, M.D., for material in 10 CFR 35.300 and 35.400.